Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Licogliflozin (LIK066) in Japanese Patients With Obesity
NCT03320941Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of licogliflozin in obesity, sponsored by Novartis. Started Dec 2017; status: completed.
02
Drugs
licogliflozin
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03320941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03320941.